Are polynucleotides better than PRP for elasticity and hydration?
Are polynucleotides better than PRP for elasticity and hydration? We don’t have head-to-head vaginal trials. PRP (from your own blood) and polynucleotides (often fish-derived) are both positioned as superficial, comfort-layer adjuncts for mild, entry-focused symptoms after pelvic floor rehab and GSM care. Polynucleotides are batch-standardised; PRP varies person-to-person. Either may help hydration and glide; neither “tightens” the vagina or treats prolapse/scar geometry. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Are polynucleotides better than PRP for elasticity and hydration? The honest answer is that we lack robust, head-to-head studies in the vagina. In intimate care, “elasticity and hydration” typically refer to the comfort layer—mucosa and vestibule—rather than deep, structural support. Most women who report “laxity” describe a blend of pelvic floor function (activation, endurance, timing), surface comfort (genitourinary syndrome of menopause, GSM/atrophy; dryness; dyspareunia; “paper-cut” micro-tears), and occasionally structure (a malpositioned perineal scar or a discrete fascial defect). Superficial injectables such as polynucleotides and platelet-rich plasma (PRP) aim to condition this comfort layer; neither corrects structural defects nor “tightens” the vagina in a meaningful mechanical sense.
What are polynucleotides? Polynucleotides are purified DNA fragments (often from fish) formulated as viscoelastic gels. In dermatology they are used to support hydration and tissue remodelling through biostimulation—signalling pathways that encourage a calmer, better-hydrated extracellular environment. Because they are manufactured, their concentration and rheology are standardised lot-to-lot. The potential advantage is consistency. The potential limitation is allergy risk for people with fish sensitivity (rare but important to screen).
What is PRP? PRP is your own blood processed to concentrate platelets and growth factors. It is autologous (low allergy risk) but highly individual: concentration depends on your baseline platelet count, processing kit and protocol. In intimate indications it is placed very superficially at tender points (e.g., vestibule/posterior fourchette) to nudge local healing and lubrication. The potential advantage is biocompatibility and simplicity; the potential limitation is variability and the need for venepuncture and processing.
Where do they sit in a pathway? We use a conservative-first framework. Start with supervised pelvic floor muscle training (activation, long holds 6–10 s, quick squeezes, and the pre-cough “knack”) and meticulous GSM care: a scheduled vaginal moisturiser 2–4 nights weekly, plus a generous, compatible lubricant for higher-friction moments (water-based for versatility/condoms; silicone-based for the longest glide; avoid oils with latex). If acceptable, consider low-dose local vaginal oestrogen to re-mature epithelium over 2–6 weeks. Only if a specific, mild, entry-focused gap persists—recurrent micro-tears, focal sting at the posterior fourchette, unpredictable early penetration—do we consider a short series of superficial injectables.
So which should I choose if I’m a candidate? Because evidence is limited and heterogeneous, the decision is practical and personalised. If you prefer a standardised, off-the-shelf gel with predictable rheology, a polynucleotide may appeal (screen for fish/seafood allergy). If you prefer an autologous option with very low allergy risk and accept some variability, PRP is reasonable. Either way, set modest goals: calmer sting, fewer “paper-cuts”, steadier glide—not dramatic “tightening”. Introduce one new modality at a time, review at 6–12 weeks after a 2–3 session series, and stop if benefits are modest.
Safety and governance. With either option, expect brief stinging at injection sites, a sensation of fullness, pinpoint bruising or light spotting for 24–72 hours. Defer all procedures with active BV/thrush/UTI, fever, malodorous discharge, recent pelvic surgery, or new post-menopausal bleeding. Products should carry appropriate UKCA/CE marking and be used within intended purpose; if a brand must be mentioned for clarity, “® belongs to its owner”. For our practical decision steps see how treatment steps are sequenced, and for inclusions/cost planning see treatment prices.
Key takeaways. Neither PRP nor polynucleotides “tighten” the vagina or treat prolapse/scar geometry; both may support hydration and comfort at the entrance for selected women after excellent foundations. Choose based on preferences (autologous vs standardised), allergy profile, logistics, and prior response to conservative care.
Clinical Context
Who might benefit? Postnatal or peri-/post-menopausal women with mild, entry-focused dyspareunia, vestibular sting or recurrent “paper-cut” fissures despite a strong block of pelvic floor rehabilitation and well-managed GSM (moisturiser, generous compatible lubricant, and—if acceptable—local oestrogen). Goals are functional: smoother early penetration, fewer micro-tears, improved tampon/speculum comfort.
Who should avoid or defer? Anyone with active infection, foul discharge, fever, heavy bleeding, visible haematuria, or new post-menopausal bleeding; those with pain-dominant/overactive pelvic floor patterns needing down-training; and women with suspected structural drivers (malpositioned perineal scar, discrete fascial defect/prolapse beyond the introitus) who merit targeted assessment instead of repeat injectables.
Next steps now. Keep a 6–12-week diary: sting scores, micro-tear/spotting days, air-trapping episodes, tampon stability, and ease at first penetration. Use it at review to decide whether to trial a short, well-spaced series (typically 2–3 sessions 4–8 weeks apart) with clear stop-rules.
Evidence-Based Approaches
NHS (patient-friendly foundations): Practical guides for pelvic floor exercises and for managing vaginal dryness after menopause underpin first-line care.
NICE menopause guideline (NG23): Recommends vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life—core measures to optimise before considering injectables. NICE NG23.
BNF (product monographs): Prescribing details and cautions for vaginal oestrogens (useful when GSM contributes to dyspareunia and micro-tears). BNF – vaginal oestrogens.
Cochrane Library (women’s pelvic health): Systematic reviews emphasise the strength of pelvic floor muscle training and conservative strategies; evidence for procedure-based intimate treatments remains heterogeneous and short-term. Cochrane Library.
PubMed (public abstracts): Overviews of GSM pathophysiology (epithelial thinning, pH/microbiome changes) explain why moisturisers, lubricants and local oestrogen reduce dyspareunia and perceived “laxity”; small studies report symptomatic improvements with PRP or polynucleotides in superficial tissue hydration contexts, but intimate head-to-heads are lacking. PubMed – GSM overview.